Energy balance in hypothalamic obesity in response to treatment with a once-weekly GLP-1 receptor agonist
Open accessThe DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Abstract
Background/Objectives Hypothalamic obesity (HO) frequently occurs following suprasellar tumors from a combination of decreased energy expenditure and increased energy intake. Glucagon-like peptide-1 receptor agonist (GLP1RA) therapy is associated with increased satiety and energy expenditure. We hypothesized GLP1RA therapy in patients with HO would cause both lower energy intake and increased energy expenditure. Subjects/Methods Forty-two patients aged 10-26 years (median 16 years) with HO with suprasellar tumors were randomized to GLP1RA (exenatide extended release once-weekly, ExQW, n = 23) or placebo ( n = 19). Thirty seven (81%) patients completed the 36-week double-blind placebo-controlled trial. Total energy expenditure (TEE) was measured with doubly labeled water, physical activity was assessed with actigraphy, and intake was estimated with ad libitum buffet meal. Results are presented as adjusted mean between-group difference. Results As compared with treatment with placebo, treatment with ExQW was associated with decreased energy intake during a buffet meal (−1800 kJ (−430 kcal), 95% CI −3 184 to −418 kJ, p = 0.02). There were no significant differences in physical activity between groups. ExQW (vs. placebo) treatment was associated with a decrease in TEE (−695 kJ/day (−166 kcal/day), 95% CI −1 130 to −264 kJ/day, p < 0.01, adjusted for baseline TEE). The treatment effect was still significant after further adjustment for change in body composition (−372 kJ/day (−89 kcal/day), 95% CI −699 to −42 kJ/day, p = 0.04) or change in leptin (−695 kJ/day (−166 kcal/day), 95% CI −1 130 to −264 kJ/day, p < 0.01). This decrease in TEE occurred despite an increase in lean mass and fat mass (1.7 vs. 1.3 kg lean mass, p = 0.88 and 1.5 vs. 4.6 kg fat mass, p = 0.04, ExQW vs. placebo). Conclusions Treatment with a GLP1RA was associated with a decrease in food intake but also a decrease in TEE that was disproportionate to change in body composition.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Validation of Accelerometer Wear and Nonwear Time Classification Algorithm
CHOI, L., LIU, Z., MATTHEWS, C. E., & BUCHOWSKI, M. S. (2011) · Medicine & Science in Sports & Exercise · doi:10.1249/mss.0b013e3181ed61a3 · Cited by 1,804
Self-citationDevelopment of the Children’s Eating Behaviour Questionnaire
Wardle, J., Guthrie, C. A., Sanderson, S., & Rapoport, L. (2001) · Journal of Child Psychology and Psychiatry · doi:10.1111/1469-7610.00792 · Cited by 1,747
GLP-1 agonism stimulates brown adipose tissue thermogenesis and browning through hypothalamic AMPK
Beiroa, D., Imbernon, M., Gallego, R., Senra, A., Herranz, D., Villarroya, F., Serrano, M., Fernø, J., Salvador, J., Escalada, J., et al. (2014) · Diabetes · doi:10.2337/db14-0302 · Cited by 602 · cited 1×
“GLP1RA may also increase energy expenditure through increased sympathetic nervous system activity and increased activation of brown adipose tissue (21, 22).”
BackgroundThe validity of self-reported energy intake as determined using the doubly labelled water technique
Hill, R. J., & Davies, P. S. W. (2001) · British Journal of Nutrition · doi:10.1079/bjn2000281 · Cited by 589 · cited 1×
“Patients with obesity have repeatedly been shown to underreport food intake by 19–59% compared with measured TEE, consistent with our observed rate of underreporting (24).”
ResultRosenbaum, M. (2005) · Journal of Clinical Investigation · doi:10.1172/jci25977 · Cited by 575 · cited 1×
“Replacement of leptin post weight loss reverses approximately 2/3 of the energy expenditure changes (31), indicating that other mechanisms are involved and perhaps important in patients with HO.”
BackgroundAdaptive thermogenesis in humans
Rosenbaum, M., & Leibel, R. L. (2010) · International Journal of Obesity · doi:10.1038/ijo.2010.184 · Cited by 349 · cited 1×
“Decreased TEE is expected with significant weight loss [29], however, our treatment group gained weight less rapidly than the placebo group rather than losing weight.”
BackgroundDoubly labelled water assessment of energy expenditure: principle, practice, and promise.
Westerterp, K. R. (2017) · European Journal of Applied Physiology · doi:10.1007/s00421-017-3641-x · Cited by 219 · cited 2×
“In brief, through periodic urine collection, DLW estimates carbon dioxide production by measuring the elimination of the tracers deuterium ((2)H) and oxygen-18 ((18)O) from the body [9, 11].”
BackgroundHarz, K. J., Müller, H. L., Waldeck, E., Pudel, V., & Roth, C. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2002-021797 · Cited by 214 · cited 2×
“Although some patients with HO have significant hyperphagia, it is not a consistent finding [1, 2, 7, 8].”
BackgroundSelf-citationModels of energy homeostasis in response to maintenance of reduced body weight
Rosenbaum, M., & Leibel, R. L. (2016) · Obesity · doi:10.1002/oby.21559 · Cited by 95 · cited 1×
“In adults with weight loss, leptin is an important signal that regulates energy expenditure via a threshold model; when fat mass decreases and leptin levels drop below a threshold, energy expenditure decreases (30).”
BackgroundMüller, H. L. (2010) · International Journal of Endocrinology · doi:10.1155/2010/519607 · Cited by 77 · cited 1×
“Hyperphagic Severity 5 (3, 6) 4 (3, 5) 0.”
Cited by
Clinical Consequences of Delayed Gastric Emptying With GLP-1 Receptor Agonists and Tirzepatide
Jalleh, R. J., Plummer, M. P., Marathe, C. S., Umapathysivam, M. M., Quast, D. R., Rayner, C. K., Jones, K. L., Wu, T., Horowitz, M., & Nauck, M. A. (2024) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgae719 · Cited by 157
“The majority of studies indicate that both short-and long-acting GLP-1RAs reduce energy intake in health (27), obesity (55-59), T1D (60), and T2D (22, 27, 61-63) with only 1 study (with liraglutide in T2D) failing to show a significant reduction in energy intake compared to placebo (28) [Fig.”
Müller, H. L., Tauber, M., Lawson, E. A., Özyurt, J., Bison, B., Martinez-Barbera, J.-P., Puget, S., Merchant, T. E., & van Santen, H. M. (2022) · Nature Reviews Disease Primers · doi:10.1038/s41572-022-00351-z · Cited by 144
Jalleh, R. J., Marathe, C. S., Rayner, C. K., Jones, K. L., Umapathysivam, M. M., Wu, T., Quast, D. R., Plummer, M. P., Nauck, M. A., & Horowitz, M. (2024) · Endocrinology · doi:10.1210/endocr/bqae155 · Cited by 61
Acquired hypothalamic obesity: A clinical overview and update
Roth, C. L., & McCormack, S. E. (2024) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.15530 · Cited by 42
“The exenatide-related decrease in total energy expenditure also occurred despite a treatment-related increase in lean mass and fat mass. 106 Overall, while almost half of exenatide-treated participants had a decrease in BMI, the other half did not respond to treatment, highlighting the need for…”
BackgroundSelf-citationTreatment of Hypothalamic Obesity With GLP-1 Analogs
Dimitri, P., & Roth, C. L. (2024) · Journal of the Endocrine Society · doi:10.1210/jendso/bvae200 · Cited by 25
Self-citation
Metadata
- Authors
- Shoemaker, A. H., Silver, H. J., Buchowski, M., Slaughter, J. C., Yanovski, J. A., Elfers, C., Roth, C. L., & Abuzzahab, M. J.
- Venue
- International Journal of Obesity
- Published
- 2022-01-03
- Volume
- 46
- Issue
- 3
- Pages
- 623-629
- ISSN
- 0307-0565 (ISSN-L)
- 1476-5497
- OpenAlex
- W4205946597
- Cited by
- 38
- References
- 12
- FWCI
- 3.28
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Energy balance in hypothalamic obesity in response to treatment with a once-weekly GLP-1 receptor agonist. https://app.cochat.ai/papers/10.1038/s41366-021-01043-6
- The paper
- Shoemaker, A. H., Silver, H. J., Buchowski, M., Slaughter, J. C., Yanovski, J. A., Elfers, C., Roth, C. L., & Abuzzahab, M. J. (2022). Energy balance in hypothalamic obesity in response to treatment with a once-weekly GLP-1 receptor agonist. International Journal of Obesity. https://doi.org/10.1038/s41366-021-01043-6
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.